论文部分内容阅读
目的:探讨二甲双胍联合羟苯磺酸钙治疗糖尿病性白内障的效果及其对外周血中白细胞介素-1β和基质金属蛋白酶(MMP-9)含量的影响。方法:选择糖尿病性白内障患者84例,按照随机原则分为对照组和实验组。对照组给予口服二甲双胍治疗,实验组在口服二甲双胍的基础上加用羟苯磺酸钙治疗。观察两组治疗前后血糖情况;检测两组治疗前后外周血中IL-1β和MMP-9含量。结果:治疗后,两组患者的空腹血糖、餐后两小时血糖、糖化血红蛋白均显著下降(P<0.05),且两组之间差异无统计学意义(P>0.05);治疗3个月后和6个月后实验组外周血中IL-1β和MMP-9含量均显著低于对照组(P<0.05)。结论:二甲双胍联合羟苯磺酸钙治疗可有效降低患者外周血中IL-1β和MMP-9含量,治疗糖尿病性白内障效果显著,值得临床推广。
Objective: To investigate the effect of metformin combined with calcium dobesilate in the treatment of diabetic cataract and its effect on the levels of interleukin-1β and matrix metalloproteinase (MMP-9) in peripheral blood. Methods: Eighty-four patients with diabetic cataract were selected and randomly divided into control group and experimental group. The control group was treated with metformin orally, and the experimental group was treated with calcium dobesilate on the basis of oral metformin. The blood glucose level before and after treatment was observed. The levels of IL-1β and MMP-9 in peripheral blood were measured before and after treatment. Results: After treatment, fasting blood glucose, postprandial blood glucose and HbA1c in both groups were significantly decreased (P <0.05), and there was no significant difference between the two groups (P> 0.05). After 3 months of treatment And 6 months later, the content of IL-1βand MMP-9 in the peripheral blood of the experimental group were significantly lower than those of the control group (P <0.05). CONCLUSION: Metformin combined with calcium dobesilate can effectively reduce the levels of IL-1β and MMP-9 in peripheral blood of patients. The treatment of diabetic cataract is significant and worthy of clinical promotion.